These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 17343804)

  • 1. Targeted, gene-directed enzyme prodrug therapies to tackle diversity and aggression of late stage prostate cancer.
    Khatri A; Russell PJ
    Discov Med; 2007 Feb; 7(37):39-45. PubMed ID: 17343804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel gene-directed enzyme prodrug therapies against prostate cancer.
    Russell PJ; Khatri A
    Expert Opin Investig Drugs; 2006 Aug; 15(8):947-61. PubMed ID: 16859396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent progress in gene-directed enzyme prodrug therapy: an emerging cancer treatment.
    Both GW
    Curr Opin Mol Ther; 2009 Aug; 11(4):421-32. PubMed ID: 19649987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical potential of gene-directed enzyme prodrug therapy to improve radiation therapy in prostate cancer patients.
    Vajda A; Marignol L; Foley R; Lynch TH; Lawler M; Hollywood D
    Cancer Treat Rev; 2011 Dec; 37(8):643-54. PubMed ID: 21481534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
    Roy P; Waxman DJ
    Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer.
    Connors TA
    Gene Ther; 1995 Dec; 2(10):702-9. PubMed ID: 8750009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent developments in gene-directed enzyme prodrug therapy (GDEPT) for cancer.
    Niculescu-Duvaz I; Cooper RG; Stribbling SM; Heyes JA; Metcalfe JA; Springer CJ
    Curr Opin Mol Ther; 1999 Aug; 1(4):480-6. PubMed ID: 11713763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT).
    Niculescu-Duvaz I; Friedlos F; Niculescu-Duvaz D; Davies L; Springer CJ
    Anticancer Drug Des; 1999 Dec; 14(6):517-38. PubMed ID: 10834273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives.
    Greco O; Dachs GU
    J Cell Physiol; 2001 Apr; 187(1):22-36. PubMed ID: 11241346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for enzyme/prodrug cancer therapy.
    Xu G; McLeod HL
    Clin Cancer Res; 2001 Nov; 7(11):3314-24. PubMed ID: 11705842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene-directed enzyme prodrug therapy with carboxylesterase enhances the anticancer efficacy of the conditionally replicating adenovirus AdDelta24.
    Oosterhoff D; Pinedo HM; Witlox MA; Carette JE; Gerritsen WR; van Beusechem VW
    Gene Ther; 2005 Jun; 12(12):1011-8. PubMed ID: 15729367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted prodrug approaches for hormone refractory prostate cancer.
    Aloysius H; Hu L
    Med Res Rev; 2015 May; 35(3):554-85. PubMed ID: 25529338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New strategies for the medical treatment of prostate cancer.
    Isaacs JT
    BJU Int; 2005 Dec; 96 Suppl 2():35-40. PubMed ID: 16359437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniques.
    Eaton JD; Perry MJ; Todryk SM; Mazucco RA; Kirby RS; Griffiths JR; Dalgleish AG
    Gene Ther; 2001 Apr; 8(7):557-67. PubMed ID: 11319623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene-directed enzyme prodrug therapy (GDEPT)--recognizing the present limitations of gene therapy for the treatment of cancer.
    Knox RJ
    Curr Opin Investig Drugs; 2001 Jun; 2(6):835-8. PubMed ID: 11572666
    [No Abstract]   [Full Text] [Related]  

  • 17. Prodrugs in cancer chemotherapy.
    Connors TA; Knox RJ
    Stem Cells; 1995 Sep; 13(5):501-11. PubMed ID: 8528099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors.
    Djeha AH; Thomson TA; Leung H; Searle PF; Young LS; Kerr DJ; Harris PA; Mountain A; Wrighton CJ
    Mol Ther; 2001 Feb; 3(2):233-40. PubMed ID: 11237680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene therapy for prostate cancer.
    Gdor Y; Timme TL; Miles BJ; Kadmon D; Thompson TC
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):309-21. PubMed ID: 12113054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining gene and immunotherapy for prostate cancer.
    Young JG; Green NK; Mautner V; Searle PF; Young LS; James ND
    Prostate Cancer Prostatic Dis; 2008; 11(2):187-93. PubMed ID: 17726452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.